Microbicides: latest news

Microbicides resources

  • Microbicides

    Microbicides are any substances which protect people against infection by microbes, such as viruses or bacteria, on contact with those microbes....

    From: Preventing HIV

    Information level Level 4
  • Microbicides

    A microbicide is a topical agent that, when applied to a mucosal surface, serves as a barrier to infection. Microbicides can come in the form of...

    From: HIV transmission & testing

    Information level Level 4

Microbicides features

Microbicides news from aidsmap

More news

Microbicides news selected from other sources

  • Dapivirine vaginal ring safe, acceptable for HIV prevention in teens

    A monthly vaginal ring containing the antiretroviral dapivirine has demonstrated efficacy in girls younger than 18 years, according to phase 2a study results presented at the IAS Conference on HIV Science.

    27 July 2017 | Healio
  • Rectal products for PrEP: Are they an option?

    At the IAS 2017 conference this week, Ian McGowan, MD, PhD, FRCP, from University of Pittsburgh, discussed the need for (and challenges associated with) topical HIV prevention products, and a separate team of researchers presented promising findings from a very early study of a rectal HIV-prevention douche.

    27 July 2017 | BETA blog
  • IPM receives award of up to $25 million From USAID to advance HIV prevention products for women

    The award will expedite the potential licensure and market introduction of a new HIV prevention microbicide product for women, who continue to be disproportionately affected by the global HIV/AIDS epidemic.

    26 July 2017 | Eurekalert Medicine & Health
  • IPM receives multi-year award from UK government to advance technologies for women's HIV

    The nonprofit International Partnership for Microbicides (IPM) announced today that it has received a £12 million (US$15.6 million) award over four years from the United Kingdom government through the Department for International Development to advance promising HIV and multipurpose prevention products that women could use to protect their sexual and reproductive health.

    20 July 2017 | Eurekalert Medicine & Health
  • Men often control use of women’s HIV prophylactic gel in Zambia

    In Zambia, men often control the use of a microbicide gel that is meant to give women autonomy in preventing HIV infection, according to researchers. Use of the vaginal gel, which is now in phase 3 trials, is limited by social norms that entrench male dominance, they wrote in Global Public Health.

    17 July 2017 | Healio
  • IPM's dapivirine vaginal ring now under review by European Medicines Agency

    The nonprofit International Partnership for Microbicides (IPM) is pleased to announce that its application for the monthly dapivirine vaginal ring, designed to reduce the risk of HIV-1 infection via vaginal intercourse in HIV-negative women in combination with safer sex practices, has been validated and is now under review by the European Medicines Agency (EMA).

    14 July 2017 | Eurekalert Medicine & Health
  • Women’s bacteria thwarted attempt at anti-HIV vaginal gel

    Creating new HIV prevention tools for women has proven frustratingly slow and researchers have found another hurdle: bacteria in the reproductive tract.

    02 June 2017 | STAT
  • IPM Advances Three-month HIV Prevention and Contraception Ring to Clinical Trial

    The three-month vaginal ring is designed to slowly — and simultaneously — release the antiretroviral drug dapivirine to prevent HIV and the contraceptive hormone levonorgestrel. The primary goal of the study, known as MTN-030/IPM 041, is to assess the ring’s safety and pharmacokinetics (how the body processes the two drugs). Results of the trial, including the product’s acceptability to women and their willingness to use it in the future, will inform next steps for the ring’s formulation and future trial designs.

    03 May 2017 | International Partnership for Microbicides
  • MTN begins first trial of new dapivirine ring with both anti-HIV drug and contraceptive

    Researchers hoping for a single product to protect against both HIV and unintended pregnancy took an important step toward realizing their goal with the start of a trial of a vaginal ring containing the antiretroviral drug dapivirine and a hormonal contraceptive. A dapivirine-only ring that women use a month at a time was safe and helped prevent HIV in two large trials. The new ring adds levonorgestrel and could be used for three months.

    03 May 2017 | Eurekalert Medicine & Health
  • Vaginal Ring Form of PrEP Does Not Reduce Contraceptive Effectiveness

    The antiretroviral (ARV)-containing vaginal ring form of pre-exposure prophylaxis (PrEP) that reduced HIV risk in a major trial does not lower the effectiveness of hormonal birth control. This finding assuages concerns raised by previous research that the non-nucleoside reverse transcriptase inhibitor (NNRTI) class of ARVs has been associated with a lowered effectiveness of some hormonal contraceptives.

    16 February 2017 | Poz
More news

Our information levels explained

  • Short and simple introductions to key HIV topics, sometimes illustrated with pictures.
  • Expands on the previous level, but also written in easy-to-understand plain language.
  • More detailed information, likely to include medical and scientific language.
  • Detailed, comprehensive information, using medical and specialised language.
Community Consensus Statement on Access to HIV Treatment and its Use for Prevention

Together, we can make it happen

We can end HIV soon if people have equal access to HIV drugs as treatment and as PrEP, and have free choice over whether to take them.

Launched today, the Community Consensus Statement is a basic set of principles aimed at making sure that happens.

The Community Consensus Statement is a joint initiative of AVAC, EATG, MSMGF, GNP+, HIV i-Base, the International HIV/AIDS Alliance, ITPC and NAM/aidsmap
close

This content was checked for accuracy at the time it was written. It may have been superseded by more recent developments. NAM recommends checking whether this is the most current information when making decisions that may affect your health.

NAM’s information is intended to support, rather than replace, consultation with a healthcare professional. Talk to your doctor or another member of your healthcare team for advice tailored to your situation.